
On March 22, 2010, the FDA announced that an independent U.S. academic research team had found DNA from porcine circovirus 1 (PCV1) in the ROTARIX vaccine. The FDA recommended that...

Contraindications to receiving rotavirus vaccines included a history of severe allergic reaction to a previous vaccine dose or to any component of the vaccine. ROTARIX was not recommended for infants...

On April 3, 2008, the FDA approved ROTARIX, a second live oral rotavirus vaccine for use in infants six through 24 weeks of age. Manufactured by GlaxoSmithKline, this vaccine was...

The CDC’s ACIP, which had begun discussions on RotaTeq in 2005, voted in February 2006 for all infants to receive 3 vaccine doses at 2, 4, and 6 months of...

Wyeth-Lederle was not the only pharmaceutical company working on a rotavirus in the 1990s. Both Merck and GlaxoSmithKline were actively in the development stages of a vaccine. On February 3,...

In August of 1999, the Committee on Government Reform launched an investigation into Federal vaccine policy as it pertained to possible conflicts of interest among Federal policy-makers. The Committee focused...

On March 19, 1999, the CDC published its recommendation on the use of RotaShield vaccine and reported that five cases of intussusception, a serious bowel blockage requiring medical attention, had...

Prior to the vaccine’s approval, Dr. Margaret Reynolds of the U.S. Rotavirus Efficacy Group presented information on the U.S. pre-licensing clinical trials at the February 12-13, 1997 CDC Advisory Committee...

Ages: ROTARIX live oral vaccine is approved for use in infants between the ages of six and 24 weeks (see GlaxoSmithKline product insert for recommended schedule and other indications.)Description: ROTARIX...

Ages: RotaTeq live oral vaccine is approved for use in infants between the ages of six and 32 weeks (see Merck product insert for recommended schedule and other indications.)Description: RotaTeq...